Text Size

Neuropathology and Therapeutics Addressing Glaucoma, a Prevalent Retina-Optic Nerve-Brain Disease that Causes Eyesight Impairment and Blindness

Sharif N.A.


  • 2022
  • OBM Neurobiology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Imperial College of Science and Technology, St. Mary’s Campus, London, United Kingdom; Singapore Eye Research Institute (SERI), Singapore; Duke-National University of Singapore Medical School, Singapore; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX, United States; Department of Pharmacy Sciences, Creighton University, Omaha, NE, United States; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, United States; Global Alliances and External Research, Ophthalmology Innovation Center, Santen Incorporated, Emeryville, CA, United States

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022